20/20 Biolabs vs iSpecimen
AIDX and ISPC side by side, both in engineering, accounting, research, management, and related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AIDX and ISPC compare
20/20 Biolabs is the larger company, worth 1.6 times as much as iSpecimen ($2.9M against $1.8M).
20/20 Biolabs grew revenue faster over the last twelve months (16.7% versus −92.1% for iSpecimen).
20/20 Biolabs keeps more of each dollar of sales as profit, with a net margin of −183% compared with −2449% at iSpecimen.
iSpecimen scores higher on the StockData Score (7 against 6 for 20/20 Biolabs), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AIDX | ISPC |
|---|---|---|
| Size and price | ||
| Market cap | $2.9M | $1.8M |
| Share price | $0.225 | $0.709 |
| Change, 1 year | – | −97.2% |
| Change, 5 years | – | −100.0% |
| Beta (5Y) | – | 0.61 |
| Employees | 14 | 53 |
| StockData Score | ||
| Total score | 6 | 7 (better) |
| Valuation score | 3 | 3 |
| Growth score | 2 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.4× (better) | 3.8× |
| P/B | 1.8× | 1.0× (better) |
| Fair value | $0.553 | $0.985 |
| Margin of safety | 59.3% (better) | 28.0% |
| Growth | ||
| Revenue growth (TTM) | 16.7% (better) | −92.1% |
| Revenue growth, 5Y average | – | −25.1% |
| Profitability | ||
| Gross margin | 29.6% (better) | −98.0% |
| Operating margin | −163% (better) | −2020% |
| Net margin | −183% (better) | −2449% |
| Return on equity | −239% (better) | −968% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −21.3× | – |
| Current ratio | 1.99 (better) | 0.82 |
| Altman Z-score | −8.83 (better) | −20.40 |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 4.2% | 2.3% |
| Held by insiders | 14.8% | 0.00% |
| Short interest, % of float | 0.52% | 12.1% |
Go deeper
- AIDX stock overview
- AIDX income statement
- AIDX valuation and score
- ISPC stock overview
- ISPC income statement
- ISPC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.